Publications

Merrill J, et al. LSM 2018 – Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

View Publication

Ramsey-Goldman R, et al. LSM 2017 • Cell-bound complement activation products in SLE

View Publication

Buyon J, et al. LSM 2016 – Reduction in EC4d and anti-C1q antibodies associate with clinical improvement in SLE.

View Publication

Putterman C, et al. LSM. 2014. Cell_bound complement activation products in systemic lupus erythematosus.

View Publication

Wallace D, et al. LSM. 2016. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

View Publication

AVISE CTD / AVISE Lupus

AVISE Lupus is indicated for the diagnosis of suspected SLE patients. AVISE CTD is indicated for differential diagnosis of autoimmune connective tissue diseases.

Literature Supporting the Novel AVISE CTD SLE Biomarkers

Multi-centered clinical validation demonstrating superior precision in lupus diagnosis: T Cell autoantibodies and TC4d outperform conventional lupus erythematosus biomarkers.

Kyttaris V et al.

Frontiers in Immunology, 2025

Multi-centered clinical validation of T Cell-bound C4d (TC4d) and T Cell autoantibodies (TIgG and TIgM): Sensitive and specific biomarkers of SLE with enhanced accuracy compared to conventional SLE tests.

Kyttaris V et al.

Arthritis Rheumatol. 2024

Enhancing systemic lupus erythematosus diagnosis: Comparative performance characteristics of TC4d and anti-T Cell Antibodies with conventional biomarkers.

Concoff et al.

Arthritis Rheumatol. 2023

Systemic evaluation of lymphocyte-bound C4d and immunoglobulins for diagnosis and activity monitoring of systemic lupus erythematosus.

Huang et al.

Clinical Biochemistry 2023

Anti-lymphocyte autoantibodies generate T Cell–C4d signatures in systemic lupus erythematosus.

Liu et al.

Translational Research 2014

Literature Supporting the Novel AVISE CTD RA Biomarkers

Anti-RA33 autoantibodies are unique, sensitive biomarkers for the identification of seronegative rheumatoid arthritis in a U.S. cohort.

Concoff et al.

Arthritis Rheumatol. 2024

Maximizing diagnostic sensitivity: Combined anti-RA33, anti-CarP, and anti-PAD4 autoantibodies in seronegative rheumatoid arthritis.

Concoff et al.

Arthritis Rheumatol. 2024

Determination of autoantibody isotypes increases the sensitivity of serodiagnostics in rheumatoid arthritis.

Sieghart et al.

Frontiers in Immunology 2018

Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.

Nell et al.

Annals of the Rheumatic Diseases 2005

Clinical Validity

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE).

Conklin J et al.

Lupus Science & Medicine 2022

A multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to American College of Rheumatology-classified lupus.

Ramsey-Goldman R et al.

ACR Open Rheumatology 2021

Complement activation occurs in patients with probable systemic lupus erythematosus and may predict progression to ACR classified SLE.

Ramsey-Goldman R et al.

Arthritis & Rheumatology 2020

Cell-bound complement activation products associate with lupus severity in SLE.

Arriens C et al.

Lupus Science & Medicine 2020

Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.

Hui-Yen J et al.

Lupus 2018

Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.

Wallace D et al.

Lupus Science & Medicine 2016

Cell-bound complement activation products in systemic lupus erythematosus.

Putterman C et al.

Lupus Science & Medicine 2014

Clinical Utility

Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.

O'Malley T et al.

Journal of Managed Care + Specialty Pharmacy 2022

A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.

Alexander RV et al.

Lupus Science & Medicine 2021

Utility of the AVISE Connective Tissue Disease test in predicting lupus diagnosis and progression.

Liang E et al.

Lupus Science & Medicine 2020

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.

Wallace D et al.

Lupus Science & Medicine 2019

The AVISE Lupus test and cell-bound complement activation products aid the diagnosis of systemic lupus erythematosus.

Mossell J et al.

The Open Rheumatology Journal 2016

Health Economic Outcome Research

Evaluation of the economic benefit of earlier systemic lupus erythematosus (SLE) diagnosis using a multivariate assay panel (MAP).

Clarke A et al.

ACR Open Rheumatology 2020

Analytical Validity

Validation of multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.

Dervieux T et al.

Journal of Immunological Methods 2017

Review Articles

A Review of Complement Activation in SLE.

Weinstein A et al.

Current Rheumatology Reports 2021

Cell-bound complement activation products in SLE.

Ramsey-Goldman R et al.

Lupus Science and Medicine 2017

Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification

Ahearn J et al.

Expert Review of Clinical Rheumatology 2017

Case Study

Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPs).

Lamichhane D et al.

Lupus 2016

AVISE SLE Monitor and Prognostic

Clinical Validity

Antiphospholipid antibodies are persistently positive at high titers. Additive value of platelet-bound C4d.

Sciascia S et al.

Frontiers in Immunology 2022

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE.

Merrill JT et al.

Lupus Science & Medicine 2018

Performance characteristics of different anti-double-stranded DNA antibody assays in the monitoring of systemic lupus erythematosus.

Mahler M et al.

Journal of Immunology Research 2017

Reduction in erythrocyte-bound complement activation products and titers of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.

Buyon J et al.

Lupus Science & Medicine 2016

Anti-C1q antibodies in systemic lupus erythematosus

Orbai AM et al.

Lupus 2015

Anti-C1q antibodies have a higher correlation with flares of lupus nephritis than other serum markers.

Akhter E et al.

Lupus 2012

Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus.

Kao A et al.

Arthritis & Rheumatology 2010

Erythrocyte C4d and Complement Receptor 1 in Systemic Lupus Erythematosus.

Singh V A et al.

The Journal of Rheumatology 2008

AVISE HCQ

AVISE HCQ is indicated for SLE patients receiving Hydroxychloroquine therapy as an objective measure of drug exposure.

Clinical Validity

Interpreting hydroxychloroquine blood levels for medication non-adherence: a pharmacokinetic study.

Balevic S et al.

Lupus Science & Medicine 2024

Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy.

Petri M et al.

Arthritis & Rheumatology 2020

A prospective international study on adherence to treatment in 305 patients with flaring SLE: Assessment by drug levels and self-administered questionnaires.

Costedoat-Chalumeau N et al.

Clinical Pharmacology and Therapeutics 2019

Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study).

Costedoat-Chalumeau N et al.

Annals of the Rheumatic Diseases 2013

Analytical Validity

Capillary blood collected on volumetric absorptive microsampling (VAMS) device for monitoring hydroxychloroquine in rheumatoid arthritis patients.

Qu Y et al.

Journal of Pharmaceutical and Biomedical Analysis 2017

AVISE HCQ Review Articles

Hydroxychloroquine blood levels in systemic lupus erythematosus: Clarifying dosing controversies and improving adherence.

Durcan L et al.

The Journal of Rheumatology 2015

Anti-Carbamylated Protein Antibodies (Anti-CarP)

Reevaluating serologic markers of poor prognostic factors in rheumatoid arthritis.

Weinstein A et al.

The Journal of Rheumatology 2019

Association of the presence of anti-carbamylated protein antibodies in early arthritis with a poorer clinical and radiologic outcome: Data from the French ESPOIR cohort.

Truchetet ME et al.

Arthritis & Rheumatology 2017

Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

Shi J et al.

PNAS 2011